Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8044858PMC
http://dx.doi.org/10.3389/fneur.2021.666657DOI Listing

Publication Analysis

Top Keywords

editorial neuropsychiatry
4
neuropsychiatry dreaming
4
dreaming brain
4
brain mechanisms
4
mechanisms clinical
4
clinical presentations
4
editorial
1
dreaming
1
brain
1
mechanisms
1

Similar Publications

Introduction: Anthropometric, demographic, genetic, and clinical features may affect cognitive, behavioral, and functional decline, while clinical trials seldom consider minimal clinically important differences (MCIDs) in their analyses.

Methods: MCIDs were reviewed taking into account features that may affect cognitive, behavioral, or functional decline in clinical trials of new disease-modifying therapies.

Results: The higher the number of comparisons of different confounders in statistical analyses, the lower values will be significant.

View Article and Find Full Text PDF

Objectives: Subjective memory complaints, increasingly common among older adults, may indicate early cognitive decline or dementia. , a herbal medicine in Korean medicine, has shown potential cognitive benefits in preclinical studies through neuroprotective and anti-inflammatory properties. Given limited efficacy of current pharmacological treatments for cognitive impairment and growing interest in natural products, investigating extract in humans is warranted.

View Article and Find Full Text PDF

Objectives: To develop and compare machine learning models to classify individuals vulnerable to Hwa-byung (HB) using an existing HB personality scale and to evaluate the efficacy of these models in predicting HB vulnerability.

Methods: We analyzed data from 500 Korean adults (aged 19-44) using HB personality and symptom scales. We used various machine learning techniques, including the random forest classifier (RFC), XGBoost classifier, logistic regression, and their ensemble method (RFC-XGC-LR).

View Article and Find Full Text PDF

Background: Recurrent attacks in neuromyelitis optica spectrum disorders (NMOSDs) or myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) can lead to severe disability. We aimed to analyse the real-world use of immunotherapies in patients with NMOSD and MOGAD, focusing on changes in treatment strategies, effects on attack rates (ARR) and risk factors for attacks.

Methods: This longitudinal registry-based cohort study included 493 patients (320 with aquaporin-4 immunoglobulin G (AQP4-IgG) seropositive NMOSD (65%), 44 with AQP4-IgG seronegative NMOSD (9%) and 129 MOGAD (26%)) with 1247 treatments from 19 German and one Austrian centre from the registry of the neuromyelitis optica study group (NEMOS).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!